EA003069B1 - Способ получения раствора для назального спрея, содержащего половые гормоны и циклодекстрин - Google Patents
Способ получения раствора для назального спрея, содержащего половые гормоны и циклодекстрин Download PDFInfo
- Publication number
- EA003069B1 EA003069B1 EA200100316A EA200100316A EA003069B1 EA 003069 B1 EA003069 B1 EA 003069B1 EA 200100316 A EA200100316 A EA 200100316A EA 200100316 A EA200100316 A EA 200100316A EA 003069 B1 EA003069 B1 EA 003069B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cyclodextrin
- solution
- estradiol
- concentration
- purified water
- Prior art date
Links
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 41
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 33
- 239000003163 gonadal steroid hormone Substances 0.000 title claims abstract description 16
- 229940097496 nasal spray Drugs 0.000 title claims abstract description 5
- 239000007922 nasal spray Substances 0.000 title claims abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000008213 purified water Substances 0.000 claims abstract description 27
- 229960005309 estradiol Drugs 0.000 claims abstract description 25
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 24
- 229930182833 estradiol Natural products 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 20
- 229940088597 hormone Drugs 0.000 claims abstract description 17
- 239000005556 hormone Substances 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 229960003604 testosterone Drugs 0.000 claims abstract description 10
- 239000000583 progesterone congener Substances 0.000 claims abstract description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 3
- 238000004108 freeze drying Methods 0.000 claims abstract description 3
- 150000000319 19-nortestosterones Chemical class 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 11
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 6
- 229960001652 norethindrone acetate Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 3
- MWCMKTVYZSKEDS-UHFFFAOYSA-N 1-(3-methoxy-4-phenylmethoxyphenyl)piperazine Chemical compound COC1=CC(N2CCNCC2)=CC=C1OCC1=CC=CC=C1 MWCMKTVYZSKEDS-UHFFFAOYSA-N 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 22
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 12
- 239000000186 progesterone Substances 0.000 description 10
- 229960003387 progesterone Drugs 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940100656 nasal solution Drugs 0.000 description 6
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000003098 androgen Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960003851 estradiol hemihydrate Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- -1 ethylnestradiol Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229960003575 estradiol acetate Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 230000009970 fire resistant effect Effects 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960004190 nomegestrol acetate Drugs 0.000 description 1
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000003128 pregnanes Chemical class 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Nanotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9812836A FR2784584B1 (fr) | 1998-10-14 | 1998-10-14 | Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine |
| PCT/FR1999/002480 WO2000021503A1 (fr) | 1998-10-14 | 1999-10-13 | Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200100316A1 EA200100316A1 (ru) | 2002-02-28 |
| EA003069B1 true EA003069B1 (ru) | 2002-12-26 |
Family
ID=9531516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100316A EA003069B1 (ru) | 1998-10-14 | 1999-10-13 | Способ получения раствора для назального спрея, содержащего половые гормоны и циклодекстрин |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1121100B1 (https=) |
| JP (1) | JP3911125B2 (https=) |
| KR (1) | KR100462441B1 (https=) |
| CN (1) | CN1323198A (https=) |
| AT (1) | ATE237310T1 (https=) |
| AU (1) | AU756441B2 (https=) |
| BR (1) | BR9914532A (https=) |
| CA (1) | CA2346567C (https=) |
| DE (1) | DE69907005T2 (https=) |
| DK (1) | DK1121100T3 (https=) |
| EA (1) | EA003069B1 (https=) |
| ES (1) | ES2197672T3 (https=) |
| FR (1) | FR2784584B1 (https=) |
| HK (1) | HK1040201A1 (https=) |
| HU (1) | HUP0103968A3 (https=) |
| NO (1) | NO20011673D0 (https=) |
| NZ (1) | NZ510776A (https=) |
| PL (1) | PL347322A1 (https=) |
| PT (1) | PT1121100E (https=) |
| WO (1) | WO2000021503A1 (https=) |
| ZA (1) | ZA200102961B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2623066C2 (ru) * | 2012-01-20 | 2017-06-21 | Аратана Терапьютикс Нв | Композиция глазных капель |
| RU2753511C2 (ru) * | 2017-05-31 | 2021-08-17 | Аратана Терапьютикс, Инк. | Композиция глазных капель |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
| EP1661556A4 (en) * | 2003-08-20 | 2010-05-19 | Ajinomoto Kk | MEDICAL PREPARATION WITH IMPROVED RESOLUTION CHARACTERISTICS |
| GB2482868A (en) * | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
| EA201490746A3 (ru) * | 2011-10-07 | 2016-09-30 | Флорида Стейт Юниверсити Рисеч Фондэйшн | Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| DE4207922A1 (de) * | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| BE1007402A5 (nl) * | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
-
1998
- 1998-10-14 FR FR9812836A patent/FR2784584B1/fr not_active Expired - Fee Related
-
1999
- 1999-10-13 PL PL99347322A patent/PL347322A1/xx unknown
- 1999-10-13 CN CN99812123A patent/CN1323198A/zh active Pending
- 1999-10-13 AU AU60967/99A patent/AU756441B2/en not_active Ceased
- 1999-10-13 WO PCT/FR1999/002480 patent/WO2000021503A1/fr not_active Ceased
- 1999-10-13 AT AT99947567T patent/ATE237310T1/de not_active IP Right Cessation
- 1999-10-13 JP JP2000575479A patent/JP3911125B2/ja not_active Expired - Fee Related
- 1999-10-13 BR BR9914532-4A patent/BR9914532A/pt not_active Application Discontinuation
- 1999-10-13 HK HK02102010.0A patent/HK1040201A1/zh unknown
- 1999-10-13 HU HU0103968A patent/HUP0103968A3/hu unknown
- 1999-10-13 EA EA200100316A patent/EA003069B1/ru not_active IP Right Cessation
- 1999-10-13 ES ES99947567T patent/ES2197672T3/es not_active Expired - Lifetime
- 1999-10-13 DK DK99947567T patent/DK1121100T3/da active
- 1999-10-13 DE DE69907005T patent/DE69907005T2/de not_active Expired - Fee Related
- 1999-10-13 NZ NZ510776A patent/NZ510776A/xx unknown
- 1999-10-13 CA CA002346567A patent/CA2346567C/fr not_active Expired - Fee Related
- 1999-10-13 KR KR10-2001-7004679A patent/KR100462441B1/ko not_active Expired - Fee Related
- 1999-10-13 EP EP99947567A patent/EP1121100B1/fr not_active Expired - Lifetime
- 1999-10-13 PT PT99947567T patent/PT1121100E/pt unknown
-
2001
- 2001-04-03 NO NO20011673A patent/NO20011673D0/no not_active Application Discontinuation
- 2001-04-10 ZA ZA200102961A patent/ZA200102961B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2623066C2 (ru) * | 2012-01-20 | 2017-06-21 | Аратана Терапьютикс Нв | Композиция глазных капель |
| RU2753511C2 (ru) * | 2017-05-31 | 2021-08-17 | Аратана Терапьютикс, Инк. | Композиция глазных капель |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0103968A2 (hu) | 2002-04-29 |
| FR2784584A1 (fr) | 2000-04-21 |
| BR9914532A (pt) | 2001-11-06 |
| ZA200102961B (en) | 2001-11-20 |
| EP1121100A1 (fr) | 2001-08-08 |
| KR100462441B1 (ko) | 2004-12-17 |
| ATE237310T1 (de) | 2003-05-15 |
| JP3911125B2 (ja) | 2007-05-09 |
| AU756441B2 (en) | 2003-01-16 |
| CA2346567A1 (fr) | 2000-04-20 |
| NZ510776A (en) | 2002-10-25 |
| KR20010073214A (ko) | 2001-07-31 |
| HUP0103968A3 (en) | 2002-06-28 |
| JP2002527374A (ja) | 2002-08-27 |
| NO20011673L (no) | 2001-04-03 |
| DE69907005T2 (de) | 2004-03-18 |
| CN1323198A (zh) | 2001-11-21 |
| PT1121100E (pt) | 2003-07-31 |
| ES2197672T3 (es) | 2004-01-01 |
| DE69907005D1 (de) | 2003-05-22 |
| FR2784584B1 (fr) | 2002-09-20 |
| EA200100316A1 (ru) | 2002-02-28 |
| EP1121100B1 (fr) | 2003-04-16 |
| DK1121100T3 (da) | 2003-07-21 |
| PL347322A1 (en) | 2002-03-25 |
| NO20011673D0 (no) | 2001-04-03 |
| HK1040201A1 (zh) | 2002-05-31 |
| CA2346567C (fr) | 2005-06-14 |
| AU6096799A (en) | 2000-05-01 |
| WO2000021503A1 (fr) | 2000-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5089482A (en) | Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin | |
| TW487583B (en) | A pharmaceutical tablet for controlled release of steroids from sugar coatings | |
| US4154820A (en) | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers | |
| CA2470703C (en) | Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
| US5955454A (en) | Nasal pharmaceutical composition containing a progestogen | |
| US20040110732A1 (en) | Pharmaceutical composition for transdermal or transmucosal administration comprising at least one progestin and/or at least one oestrogen, process for preparing it and uses thereof | |
| KR20080091156A (ko) | 입에 사용하기 위한 막 형상의 제약 형태 〔웨이퍼〕 | |
| HU181703B (en) | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents | |
| JP2004518656A5 (https=) | ||
| NO341780B1 (no) | Testosterongeler omfattende polypropylenglykol og isopropylmyristat som gjennomtrengningsforsterker | |
| CA3157999A1 (en) | Injectable compositions of ursodeoxycholic acid | |
| EA003069B1 (ru) | Способ получения раствора для назального спрея, содержащего половые гормоны и циклодекстрин | |
| JPH09502709A (ja) | エストロン誘導体及びカルシウム塩含有の経口、水溶性製薬組成物 | |
| JPS62205024A (ja) | エストロゲン欠乏症治療用組成物 | |
| MXPA01003410A (en) | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin | |
| JP3754466B2 (ja) | ジエノゲストを有効成分とするホルモン療法用制癌剤 | |
| CN109381424A (zh) | 稳定的黄体酮水溶注射剂及其制备方法 | |
| NZ553446A (en) | Testosterone gels comprising propylene glycol as penetration enhancer | |
| CN110694075A (zh) | 一种醋酸乌利司他-环糊精包合物的制备方法 | |
| ZA200106689B (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding. | |
| MXPA01008772A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |